9 Automated AJCC (7th edition) staging of non-small cell lung cancer (NSCLC) using deep convolutional neural network (CNN) and recurrent neural network (RNN).

10 Afatinib for the treatment of metastatic non-small cell lung cancer

11 Afatinib for the treatment of metastatic non-small cell lung cancer

12 Afatinib for the treatment of metastatic non-small cell lung cancer

13 Analysis of Prognostic Factors in 541 Female Patients with Advanced Non-small Cell Lung Cancer

14 Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).

15 Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

16 Retraction notice to “miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog” (Biochemical and Biophysical Research Communications (2016) 480(3) (369–374), (S0006291X16317338), (10.1016/j.bbrc.2016.10.055))

17 Retraction notice to “The miR-599 promotes non-small cell lung cancer cell invasion via SATB2” (Biochemical and Biophysical Research Communications (2017) 485(1) (35–40), (S0006291X17302668), (10.1016/j.bbrc.2017.02.005))

18 Correction: Artocarpin, an isoprenyl flavonoid, induces p53-dependent or independent apoptosis via ROS-mediated MAPKs and Akt activation in non-small cell lung cancer cells.

19 [Effects of Interference with UCA1 and Inhibition of miR-185-5p on Activation, Autophagy and Survival of β-Catenin Pathway in Non-small Cell Lung Cancer].

20 The effect of socioeconomic status on treatment and mortality in non-small cell lung cancer patients.

21 Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Cancer: A Case Report.

22 Joint Serum Tumor Markers Serve as survival predictive model of Erlotinib in the treatment of recurrent Non-small Cell Lung Cancer

23 Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features.

24 Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.

25 CBLL1 is highly expressed in non‐small cell lung cancer and promotes cell proliferation and invasion

26 Long non-coding RNA TUG1 enhances chemosensitivity in non-small cell lung cancer by impairing microRNA-221-dependent PTEN inhibition.

27 Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial

28 Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

29 Inclusion of Incidental Radiation Dose to the Cardiac Atria and Ventricles Does Not Improve the Prediction of Radiation Pneumonitis in Advanced-Stage Non-Small Cell Lung Cancer Patients Treated With Intensity Modulated Radiation Therapy.

30 Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells.

31 Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells.

32 A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.

33 Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?

34 Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.

35 CXCL14 and NOS1 expression in specimens from patients with stage I-IIIA nonsmall cell lung cancer after curative resection

36 Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 27 RCTs.

37 Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer.

38 Concordance Between Rapid On-Site Evaluation and Final Cytologic Diagnosis in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Non-Small Cell Lung Cancer Staging

39 Thyroid metastasis from non-small cell lung cancer.

40 Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent

41 LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.

42 Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer.

43 Screening Key Genes Associated with the Development and Progression of Non-small Cell Lung Cancer Based on Gene-enrichment Analysis and Meta-analysis

44 Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

45 Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.

46 The Relative Importance of Clinical and Socio-Demographic Variables in Prognostic Prediction in Non-Small Cell Lung Cancer: A Variable Importance Approach.

47 A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer.

48 A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.

49 Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer.

50 Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?

51 Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary Teams.

52 Genetic and Epigenetic Tumor Suppressor Gene Silencing Are Distinct Molecular Phenotypes Driven by Growth Promoting Mutations in Nonsmall Cell Lung Cancer

53 Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323.

54 surgical treatment for non-small cell lung cancer in patients on hemodialysis due to chronic kidney disease: clinical outcome and intermediate-term results

55 clinical significance of detection of serum values of neuron specific enolase  before and after treatment for small cell lung cancer

56 single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

57 over-expression of chromatin assembly factor 1 subunit a (chaf1a) facilitates cell proliferation in non-small cell lung cancer (nsclc)

58 mechanism of c-met in non-small cell lung cancer and its treatment and testing

59 chemotherapeutic drugs induce ppar-γ expression and show sequence-specific synergy with ppar-γ ligands in inhibition of non–small cell lung cancer

60 severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring egfr mutation

61 acute appendicitis from metastatic small cell lung cancer

62 economic analysis of alternative strategies for detection of alk rearrangements in non small cell lung cancer

63 overexpression of progerin results in impaired proliferation and invasion of non-small cell lung cancer cells

64 mutational analysis of hogg1 gene promoter in patients with non-small cell lung cancer

65 next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin

66 the changes of the first-line chemotherapy on advanced non-small cell lung cancer

67 prospective analysis on survival outcomes of nonsmall cell lung cancer stages over iiib treated with hangam-dan

68 significances of ret fusion gene in non-small cell lung cancer

69 up-regulation of fstl3, regulated by lncrna dscam-as1/mir-122-5p axis, promotes proliferation and migration of non-small cell lung cancer cells

70 surgical treatment for non-small cell lung cancer patients with synchronous solitary brain metastasis

71 impact of chemotherapy on symptom profile, oxidant-antioxidant balance and nutritional status in non-small cell lung cancer

72 numb chin syndrome as a manifestation of non-small cell lung cancer

73 a pilot study (swog s0429) of weekly cetuximab and chest radiotherapy for poor-risk stage iii non-small cell lung cancer

74 the humanistic burden of small cell lung cancer (sclc): a systematic review of health-related quality of life (hrqol) literature

75 analysis of the factors associated with abnormal coagulation and prognosis in patients with non-small cell lung cancer

76 editorial: update on the treatment of metastatic non-small cell lung cancer (nsclc) in new era of personalised medicine

77 clinical observation of erlotnib in the treatment of non-small cell lung cancer with multimetastases in elderly patients

78 relationship between bim gene polymorphism and therapeutic efficacy in the  retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor

79 risk factors for severe diarrhea with an afatinib treatment of non-small cell lung cancer: a pooled analysis of clinical trials

80 dabrafenib in combination with trametinib in the treatment of patients with braf v600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

81 relationship between the expression of prdm14 in non-small cell lung cancer and the clinicopathologic characteristics

82 pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report

83 triap1 knockdown sensitizes non‐small cell lung cancer to ionizing radiation by disrupting redox homeostasis

84 association between cd47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

85 analysis of subclassification by size and survival-associated factors of stageⅠnon-small cell lung cancer

86 clinicopathological significance of fascin-1 expression in patients with non-small cell lung cancer

87 effect of bufalin on proliferation and apoptosis of human non-small cell lung cancer a549 cell

88 detecção de micrometástases em câncer de pulmão não-pequenas células estádio pn0: um método alternativo combinando imunohistoquímica e análise em microsséries detection of micrometastases in pn0 non-small cell lung cancer: an alternative method combining tissue microarray and immunohistochemistry

89 clinical research of perioperative serum vegf and mmp-9 levels in patients with non-small cell lung cancer

90 effect of informing the diagnosis on depressive state in patients with non-small cell lung cancer of stage Ⅲ

91 preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to n-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer

92 quantum dots immunofluorescence histochemical detection of egfr gene mutations in the non-small cell lung cancers using mutation-specific antibodies

93 proton beam therapy for non-small cell lung cancer: current clinical evidence and future directions

94 role of fdg-pet scans in staging, response assessment, and follow-up care for non-small cell lung cancer

95 alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: report of a case and case review

96 proteomic insights into non-small cell lung cancer: new ideas for cancer diagnosis and therapy from a functional viewpoint

97 advance of second-line chemotherapy in advanced non-small cell lung cancer

98 expression of protein tyrosine kinase 6 (ptk6) in nonsmall cell lung cancer and their clinical and prognostic significance

99 expression and significance of snail and claudin-3 in non-small cell lung cancer

100 stats family expression in non-small cell lung cancer tissue and their potential target genes

101 terpinen-4-ol induces apoptosis in human nonsmall cell lung cancer in vitro and in vivo

Keyword Connections

Journals

Research Groups

Bibliographies